Boston, MA 10/04/2013 (wallstreetpr) – An important announcement has been made in the publication of Vical Incorporated (NASDAQ:VICL) journal about the progress in cutting edge vaccine developed for immunization from cytomegalovirus. This vaccine named ASP0113 (TransVax) is a therapeutic, research oriented medicine that is said to prevent from cytomegalovirus (CMV) which is most commonly found in transplant recipient patients. This vaccine was set to be commercialized by Vical Incorporated (NASDAQ:VICL) and Astellas Pharma Inc. (TYO: 4503) in 2011.
Breakthrough has come in the form of transition of this research project from initial product concept to phase 3 where trials are started.
Ongoing work at Vical Incorporated (NASDAQ:VICL)
Larry R. Smith, Ph.D., Vice President, Vaccine Research at Vical Incorporated (NASDAQ:VICL) and lead author of the new publication stated that Vical Incorporated (NASDAQ:VICL) has been a frontrunner in the invention and research of DNA vaccines since its discovery of plasmid DNA utility in the 1980’s. He also expressed that Vical Incorporated (NASDAQ:VICL) has established its standing in the vaccine industry by progressing from just research to licensed trials.
These ongoing trials are performed by their partners at Astellas Pharma Inc. (TYO: 4503) while Vical Incorporated (NASDAQ:VICL) is providing the necessary support in terms of infrastructure, regulatory, development and drug production. Smith also conveyed excitement over the prospect that whatever they are helping aid to produce has got the ability to treat infections that threaten recovery after human transplantation.
Risk of CMV
Cytomegalovirus is a herpes virus that affects immuno-suppressed adults over 40 years of age in general. Even a strong immune system is not enough to prevent infection or clear the latent infection inside the body leading to undesired circumstances. Vical Incorporated (NASDAQ:VICL) is targeting to develop two types of medicines from ASP0113. One as a recovery vaccine for transplant patients, the other is as a medicinal course to treat CMV disease.
